Comparative Pharmacology
Head-to-head clinical analysis: HEMANGEOL versus PROPRANOLOL HYDROCHLORIDE HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEMANGEOL versus PROPRANOLOL HYDROCHLORIDE HYDROCHLOROTHIAZIDE.
HEMANGEOL vs PROPRANOLOL HYDROCHLORIDE & HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hemangeol (propranolol hydrochloride) is a non-selective beta-adrenergic receptor antagonist that competitively blocks beta-1 and beta-2 receptors. In infantile hemangioma, the exact mechanism is not fully understood, but proposed actions include vasoconstriction, inhibition of angiogenesis by downregulating VEGF and bFGF, and induction of apoptosis in endothelial cells.
Propranolol is a non-selective beta-adrenergic receptor antagonist blocking beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and renin release; hydrochlorothiazide is a thiazide diuretic inhibiting sodium and chloride reabsorption in the distal convoluted tubule.
3 mg/kg/day orally divided into 2 doses for pediatric patients; adult use not indicated
Propranolol hydrochloride 40-80 mg/hydrochlorothiazide 25-50 mg orally twice daily. Maximum propranolol 640 mg/day, hydrochlorothiazide 50 mg/day.
None Documented
None Documented
3-4 hours in infants (0-1 year) and 3.5-4.5 hours in children (1-6 years); clinical context: requires TID dosing to maintain therapeutic effect.
Propranolol: 3-6 hours (terminal half-life); can increase with hepatic impairment. Hydrochlorothiazide: 6-15 hours (terminal half-life); prolonged in renal impairment.
Primarily hepatic metabolism via UGT1A9 and CYP2C9; <5% excreted unchanged in urine. Biliary/fecal elimination of metabolites; exact % not defined.
Propranolol: <1% excreted unchanged in urine; extensively metabolized in liver, metabolites excreted renally. Hydrochlorothiazide: ≥95% excreted unchanged in urine via renal tubular secretion.
Category C
Category C
Beta-Blocker
Beta-Blocker